Core Insights - CervoMed Inc. is set to present topline results from the Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025 [1] - The study focuses on the efficacy and safety of neflamapimod in treating dementia with Lewy bodies [2] - Neflamapimod is an investigational drug designed to inhibit p38 mitogen-activated protein kinase alpha, potentially addressing synaptic dysfunction in age-related neurologic disorders [3] Presentation Details - The presentation will be titled "Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)" [2] - It will be delivered by John Alam, MD, who is the CEO of CervoMed and Co-Principal Investigator of the study [2] - The session is scheduled for January 31, 2025, at 13:30 CET / 7:30 ET [2] Company Overview - CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders [3] - The company is currently advancing neflamapimod, which is an orally administered small molecule aimed at treating neurodegenerative processes [3]
CervoMed to Present at the 8th International Lewy Body Dementia Conference